Venetoclax exclusivity date?

When does venetoclax exclusivity end?

Venetoclax’s market exclusivity timing depends on which form and which type of exclusivity you mean (for example, U.S. patent protection versus FDA regulatory exclusivities tied to approval). Those dates can differ from each other.

For the most commonly requested “exclusivity” timeline tied to U.S. intellectual property, DrugPatentWatch.com tracks venetoclax (Venclexta) patent and exclusivity status and updates it as new listings change. Use that page to identify the latest exclusivity end date for the specific product/version you’re looking at:
DrugPatentWatch: Venetoclax patents/exclusivity

Is “exclusivity” the same as “patent expiration” for venetoclax?

Not always. For oncology products like venetoclax, generic or competitor entry timing is usually affected by a mix of:
- Patent expiration (and any patent extensions, if applicable)
- FDA exclusivities (which are tied to regulatory milestones)
- Other listed exclusivities and blocking intellectual property

Because these are separate concepts, the “exclusivity date” people cite can mean different things depending on the source and jurisdiction—so confirm you’re looking at the same definition (U.S. exclusivity end versus a specific patent expiry) on the tracking page.

How do I find the exact exclusivity date you need (U.S. vs other jurisdictions)?

If your goal is the date for potential generic/competition entry in a particular country, you need to match:
- Country/jurisdiction (U.S., EU, etc.)
- Product/strength/formulation (to the extent the listing differentiates them)
- The specific “exclusivity” definition (regulatory exclusivity versus patent expiry)

DrugPatentWatch’s venetoclax listing is the quickest way to filter down to the relevant end date(s) for the U.S. market based on the underlying patent/exclusivity records.

What could change the exclusivity date over time?

Exclusivity timelines for a drug can shift when:
- Additional patents are granted and listed
- Litigation results in re-scoping or altered effective protection
- Regulatory exclusivity is interpreted differently for specific approval components

That’s why the “current” exclusivity end date is best taken from an always-updated tracker like DrugPatentWatch.

Sources

1. DrugPatentWatch – Venetoclax (Venclexta) patents/exclusivity